Drug use evaluation of bevacizumab injection based on weighted TOPSIS method

doi:10.19803/j.1672-8629.20230480

Abstract

Abstract: Objective To establish the drug utilization evaluation criteria for bevacizumab and promote the rational use of bevacizumab through appropriate pharmaceutical interventions. Methods The archived medical records of 100 inpatients using bevacizumab injection in the first half of 2022 and the second half of 2022 were retrospectively analyzed. According to the instructions of bevacizumab and relevant clinical guidelines, the evaluation criteria of bevacizumab drug utilization were formulated, and the weighted advantage and inferiority solution method (TOPSIS) was used to objectively evaluate the use of bevacizumab. According to the evaluation results, the possible reasons were analyzed, and then the corresponding pharmaceutical intervention measures were formulated and continuous intervention was given. Finally, the weighted TOPSIS method was used to evaluate the use of bevacizumab after intervention. Results Before pharmaceutical intervention, there were 17 reasonable prescriptions (17.00%), 0 basic reasonable prescriptions and 83 unreasonable prescriptions (83.00%). After the intervention, there were 55 reasonable prescriptions (55.00%), 24 basically reasonable prescriptions (24.00%) and 21 unreasonable prescriptions (21.00%), which was improved compared with that before the intervention. After pharmaceutical intervention, the previous chemotherapy regimen, medication sequence, indications and combination drugs were improved, and the differences were statistically significant (P<0.05). Conclusion The weighted TOPSIS method can objectively and comprehensively evaluate the use of bevacizumab, which is convenient to find problems and intervene in time and promote the reasonable use of drugs.

Key words: bevacizumab, weighted TOPSIS method, drug use evaluation, pharmaceutical interventions, prescriptions, reasonable use of drug, neoplasms

CLC Number:

R969.3

YIN Jinjun, WANG Shuwei, SHAO Jiangchao, WANG Bing. Drug use evaluation of bevacizumab injection based on weighted TOPSIS method[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1421-1426.

References

[1] TIAN D, BEN X, WANG S, et al.Surgical resection of primary tumors improved the prognosis of patients with bone metastasis of non-small cell lung cancer:a population-based and propensity score-matched study[J]. Ann Transl Med,2021,9(9):775.
[2] CAI Q, XIE BY, HUANG XW.Meta-analysis of bevacizumab combined cisplatin for non-small cell lung cancer with malignant pleural effusion[J]. Military Medical Journal of South China(华南国防医学杂志), 2017, 31(4): 259-263, 266.
[3] SHIH T, LINDLEY C.Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies[J]. Clin Ther, 2006, 28(11): 1779-1802.
[4] MOHAMMED TJ, ALBAHRI AS, ZAIDAN AA, et al.Convalescent-plasma-transfusion intelligent framework for rescuing COVID-19 patients across centralised/decentralised telemedicine hospitals based on AHP-group TOPSIS and matching component[J].Appl Intell (Dordr), 2021, 51(5): 2956-2987.
[5] XU J, KONG LT.Pharmaceutical intervention based on weighted TOPSIS method on the rationality rate of apatinib prescription[J].Chinese Journal Of General Practice(中华全科医学), 2022, 20(9): 1598-1602.
[6] PHILLIPS MS, GAYMAN JE, TODD MW.ASHP guidelines on medication-use evaluation. American Society of Health-system Pharmacists[J].Am J Health Syst Pharm, 1996, 53(16): 1953-1955.
[7] LI SQ, BAN LL.Review on drug use evaluation at home and abroad[J].Evaluation And Analysis of Drug-use In Hospitals of China(中国医院用药评价与分析), 2021, 21(7): 893-896.
[8] XIA YQ, WU QZ.A technique of order preference by similarity to ideal solution for hybrid multiple attribute decision making problems[J]. Journal of Systems Engineering(系统工程学报), 2004, 19(6): 630-634.
[9] CHENG LL, CAO J.Application of weighted TOPSIS in comprehensive evaluatiom of hospital[J]. Chinese Journal of Hospital Statistics(中国医院统计), 2006, 13(1): 17-19.
[10] CHENG QS.Attribute hierarchy model AHM—a new unstructured decision-making method[J]. Acta Scientiarum Naturalium Universitatis Pekinensis(北京大学学报自然科学版), 1998, 34(1): 12-16.
[11] LIU JB, QU CY, WANG RH.Topsis comprehensive evaluation and its application based on attribute AHM[J]. Modern Preventive Medicine(现代预防医学), 2006, 33(10): 1862-1863.
[12] ANSARI MTJ, AL-ZAHRANI FA, PANDEY D, et al.A fuzzy TOPSIS based analysis toward selection of effective security requirements engineering approach for trustworthy healthcare software development[J].BMC Med Inform Decis Mak, 2020, 20(1): 236.
[13] ZHAO XL, ZHU QQ, ZHAO P, et al.Evaluation of recombinant human thrombopoietin utilization based on weighted TOPSIS method[J].China Journal of Hospital Pharmacy(中国医院药学杂志), 2022, 42(4): 431-434.
[14] HUANG B, HU Z, ZHU LN, et al.Establishment and application of drug utilization evaluation standard of Xiangdan injection based on weighted TOPSIS method[J]. Chinese Journal of Modern Applied Pharmacy(中国现代应用药学), 2020, 37(22): 2792-2796.
[15] WANG GF, LIU RF, LI XQ, et al.Evaluation of drug use of tigecycline based on weighted TOPSIS method[J]. China Journal of Hospital Pharmacy(中国医院药学杂志), 2019, 39(4): 381-384, 389.
[16] None. List of off-label drugs (2019 edition)[J]. Pharmacy Today(今日药学), 2020, 30(2): 73-98.
[17] None. List of off-label drugs(New usage in 2023)[J]. Pharmacy Today(今日药学), 2023, 33(7): 481-498.
[18] Working Committee of guidelines of Chinese society of clinical oncology. Guidelines of Chinese society of clinical oncology(CSCO) non-small cell lung cancer 2022[M]. Beijing: People’s Medical Publishing House(人民卫生出版社), 2022.
[19] Working Committee of guidelines of Chinese society of clinical oncology. Guidelines of Chinese society of clinical oncology(CSCO) colorectal cancer 2022[M]. Beijing: People’s Medical Publishing House(人民卫生出版社), 2022.
[20] Working Committee of guidelines of Chinese society of clinical oncology. Guidelines of Chinese society of clinical oncology(CSCO) cervical cancer 2022[M]. Beijing: People’s Medical Publishing House(人民卫生出版社), 2022.
[21] Working Committee of guidelines of Chinese society of clinical oncology. Guidelines of Chinese society of clinical oncology(CSCO) ovarian cancer 2022[M]. Beijing:People’s Medical Publishing House(人民卫生出版社), 2022.
[22] Working Committee of guidelines of Chinese society of clinical oncology. Guidelines of Chinese society of clinical oncology(CSCO) liver cancer 2022[M]. Beijing: People‘s Medical Publishing House(人民卫生出版社), 2022.
[23] Working Committee of guidelines of Chinese society of clinical oncology. Guidelines of Chinese society of clinical oncology(CSCO) renal cancer 2022[M]. Beijing: People‘s Medical Publishing House(人民卫生出版社), 2022.
[24] Working Committee of guidelines of Chinese society of clinical oncology. Guidelines of Chinese society of clinical oncology(CSCO) head and neck cancer 2022[M]. Beijing: People‘s Medical Publishing House(人民卫生出版社), 2022.
[25] Working Committee of guidelines of Chinese society of clinical oncology. Guidelines of Chinese society of clinical oncology(CSCO) breast cancer 2022[M].Beijing: People‘s Medical Publishing House(人民卫生出版社), 2022.
[26] GAO L, HE R.Current situation and analysis of bevacizumab over instruction in China[J].Drug Evaluation(药品评价), 2022, 19(17): 1084-1088.
[27] HU ZH, YANG WZ.Assessment of usage of linezolid by a pediatric department based on weighted TOPSIS method[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(10): 1128-1131.
[28] ZHU XM, GUO CL, GAO Y, et al.Clinical effect of EGFR-TKIs combined with platinum-containing chemotherapy and whole brain radiotherapy in the treatment of non-small cell lung cancer with brain metasasis[J]. Chinese Journal of Postgraduates of Medicine(中国医师进修杂志), 2019, 42(2): 109-114.
[29] AUGUSTUS E, ZWAENEPOEL K, SIOZOPOULOU V, et al.Prognostic and predictive biomarkers in non-small cell lung cancer patients on immunotherapy-the role of liquid biopsy in unraveling the puzzle[J]. Cancers (Basel), 2021, 13(7): 1675.
[30] YANG ZM, ZHU ZH, XU LS, et al.Comparison of global burden and screening of colorectal cancer[J]. Journal of Practical Oncology(实用肿瘤杂志), 2023, 38(3): 211-217.
[31] BRAY F, FERLAY J, SOERJOMATARAM I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[32] LIU SH, LI B.Appropriate choice and implementation of radical surgical procedures for cervical cancer[J]. Chinese General Practice(中国全科医学), 2022, 25(18): 2231-2234, 2254.
[33] ARBYN M, WEIDERPASS E, BRUNI L, et al.Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis[J]. Lancet Glob Health, 2020, 8(2): e191-e203.
[34] WANG SW, YIN JJ, SHAO JC, et al.Influence of radiotherapy intervention on local control of oligometastatic breast cancer[J/CD].Chinese Journal of Breast Disease (Electronic Edition)(中华乳腺病杂志电子版), 2023, 17(2): 72-79.
[35] LI BY, GUO DH, ZHU Y, et al.Automatic monitoring of thrombocytopenia caused by bevacizumab in 4 864 inpatients and related influencing factors[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(12): 1362-1367.